8,11-dihydroxy-4-(2-hydroxyethyl)-6-((2-((2-hydroxyethyl)amino)ethyl)amino)-1,2,3,4,7,12-hexahydronaphtho(2,3-f)quinoxaline-7,12-dione,
DHHNQD,
137132-70-8,
Mitoxantrone Impurity D,
8,11-dihydroxy-4-(2-hydroxyethyl)-6-(2-(2-hydroxyethylamino)ethylamino)-1,2,3,4-tetrahydronaphtho[2,3-f]quinoxaline-7,12-dione,
Dhhnqd,
Naphtho[2,3-f]quinoxaline-7,12-dione,1,2,3,4-tetrahydro-8,11-dihydroxy-4-(2-hydroxyethyl)-6-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-,
8,11-Dihydroxy-4-(2-hydroxyethyl)-6-((2-((2-hydroxyethyl)amino)ethyl)amino)-1,2,3,4,7,12-hexahydronaphtho(2,3-f)quinoxaline-7,12-dione,
AE-641/11403647,
ACMC-20mwgh,
(Mitoxantrone Impurity D)",
AC1L309N,
SCHEMBL3275895,
CTK4C0665,
DTXSID30160085,
ZINC19802029,
AKOS030241465,
FT-0672424,
Mitoxantrone (2-Hydroxyethyl)piperazine Impurity(Mitoxantrone Impurity D),
1,2,3,4-Tetrahydro-4-(2-hydroxyethyl)-6-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-8,11-dihydroxynaphtho[2,3-f]quinoxaline-7,12-dione,
1,2,3,4-Tetrahydro-8,11-dihydroxy-4-(2-hydroxyethyl)-6-[[2-[(2-hydroxyethyl)amino]ethyl]amino]naphtho[2,3-f]quinoxaline-7,12-dione,
8,11-dihydroxy-4-(2-hydroxyethyl)-6-({2-[(2-hydroxyethyl)amino]ethyl}amino)-1,2,3,4-tetrahydronaphtho[2,3-f]quinoxaline-7,12-dione,
8,11-dihydroxy-4-(2-hydroxyethyl)-6-[[2-[(2-hydroxyethyl)-amino]-ethyl]-amino]-1,2,3,4,7,12-hexahydronaphtho-[2,3-f]-quinoxaline-7,12-dione,
8,11-dihydroxy-4-(2-hydroxyethyl)-6-[2-(2-hydroxyethylamino)ethylamino]-2,3-dihydro-1H-naphtho[3,2-f]quinoxaline-7,12-dione,
Naphtho(2,3-f)quinoxaline-7,12-dione, 8,11-dihydroxy-1,2,3,4-tetrahydro-4-(2-hydroxyethyl)-6-((2-((2-hydroxyethyl)amino)ethyl)amino)-,
CID132032,
C22-H26-N4-O6,
CS-T-58865,
Mitoxantrone (2-Hydroxyethyl)piperazine Impurity,
8,11-dihydroxy-4- -6-((2-( -1,2,3,4,7,12-hexahydronaphtho quinoxaline-7,12-dione,